Ozempic's Impact on American Food Purchasing Habits

Ozempic's Impact on American Food Purchasing Habits

The impact of appetite-suppressing medications such as Ozempic and Wegovy on Americans extends beyond weight loss, influencing their food purchasing behavior. New research indicates a strong correlation between these medications and significant reductions in household spending on food, encompassing both grocery store and restaurant purchases.

A study published in the Journal of Marketing Research on December 18, examined survey data on the use of GLP-1 receptor agonists—drugs initially designed for diabetes treatment but now commonly prescribed for weight loss. This data was then cross-referenced with extensive transaction records from tens of thousands of U.S. households. The result provides a comprehensive view of how GLP-1 adoption relates to changes in everyday food purchasing habits.

The most prominent finding reveals a substantial decrease in grocery spending, averaging 5.3% within six months of starting a GLP-1 medication. For higher-income households, this reduction is even more pronounced, exceeding 8%. Furthermore, spending at fast-food establishments, coffee shops, and similar limited-service eateries drops by approximately 8%.

According to co-authors Sylvia Hristakeva and Jura Liaukonyte from the Cornell SC Johnson College of Business, households that continue using the medication maintain lower food spending for at least a year. However, the reduction's magnitude diminishes over time.

Hristakeva stated, "The data clearly illustrates changes in food spending following adoption. After discontinuation, the effects lessen and become more difficult to distinguish from pre-adoption spending patterns."

Unlike prior studies relying on self-reported eating habits, this new analysis utilizes purchase data from Numerator, a market research firm that tracks grocery and restaurant transactions for a representative panel of about 150,000 households nationwide. Researchers correlated these records with recurring surveys to determine if household members were using GLP-1 drugs, including when they initiated use and their reasons for doing so. Health tracking apps like Shotlee can help monitor medication adherence and its effects on dietary habits.

This approach enabled the team to compare individuals using the drugs with similar households not using them, allowing them to isolate changes that occurred specifically after the medication was introduced.

Shifts in Grocery Spending

The reductions observed were not uniform across all grocery categories.

The most significant declines were seen in ultra-processed, calorie-dense foods, which are typically associated with cravings. Spending on savory snacks decreased by approximately 10%, along with similarly large decreases in sweets, baked goods, and cookies. Even staple items like bread, meat, and eggs experienced declines.

Conversely, a limited number of categories showed increases. Yogurt saw the largest increase, followed by fresh fruit, nutrition bars, and meat snacks.

Hristakeva noted, "The primary trend is a reduction in overall food purchases. Only a few categories show increases, and these are modest compared to the overall decline."

These effects extended beyond supermarkets, with spending at limited-service restaurants, such as fast-food chains and coffee shops, also decreasing significantly.

Demographics and Medication Use

The study also provided insights into the demographics of GLP-1 medication users. The proportion of U.S. households with at least one user increased from approximately 11% in late 2023 to over 16% by mid-2024. Weight-loss users tended to be younger and wealthier, while those using the drugs for diabetes were older and more evenly distributed across income levels.

Interestingly, about one-third of users discontinued the medication during the study. Upon doing so, their food spending reverted to pre-adoption levels, and their grocery selections became slightly less healthy, driven by increased spending in categories like candy and chocolate.

The authors caution that the study cannot fully distinguish the biological effects of the drugs from concurrent lifestyle changes. However, clinical trial evidence, combined with the observed reversion in spending after discontinuation, suggests that appetite suppression is a major factor behind the changes in spending.

Implications for the Food Industry

These findings have significant implications beyond individual households.

For food manufacturers, restaurants, and retailers, the widespread adoption of GLP-1 drugs could lead to long-term shifts in demand, particularly for snack foods and fast food. This may require adjustments in package sizes, product formulations, and marketing strategies. For policymakers and public health experts, the results contribute to ongoing discussions about the role of medical treatments in influencing dietary behaviors and whether biologically driven appetite changes can succeed where taxes and labels have had limited success.

Hristakeva concluded, "At current adoption rates, even relatively small changes at the household level can have significant aggregate effects. Understanding these shifts in demand is crucial for assessing food markets and consumer spending."